Floatz logo

Seviteronel

Castration-Resistant Prostate Carcinoma

Innocrin PharmaceuticalSmall moleculePhase 2Dormant
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
81/ 100

Competitive context

230 Active assets in the Castration-Resistant Prostate Carcinoma cohort.

Asset / SponsorPhaseRating
Darolutamide
Bayer
Phase 4BBB
Enzalutamide
Prostate Cancer Clinical Trials Consortium
Phase 4BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Ding-Wei Ye
Phase 4BBB
RADIUM RA-223
University of California, San Francisco
Phase 4BB
Mevrometostat
Prostate Cancer Clinical Trials Consortium
Phase 3BB

View all 50 →

Same molecule, other indications

Seviteronel is also rated in:

CRPCDormant
BB
Indicative ·
69 / 100
View asset →
Androgen Receptor Gene OverexpressionDormant
CCC
Indicative ·
53 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →